A5016933642- Glioma Diagnosis and Treatment
- MicroRNA in disease regulation
- Ferroptosis and cancer prognosis
- Inflammasome and immune disorders
- interferon and immune responses
- Neuroscience and Neuropharmacology Research
- Epilepsy research and treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- Ubiquitin and proteasome pathways
- Biomarkers in Disease Mechanisms
- Cancer Research and Treatments
- Neurogenesis and neuroplasticity mechanisms
- Microtubule and mitosis dynamics
- 3D Printing in Biomedical Research
- Circular RNAs in diseases
CHA University
2021-2024
CHA Bundang Medical Center
2022-2024
Abstract Mesenchymal stem cells (MSC) are being developed as therapeutic agents for treatment of various diseases due to their high tropism damaged sites and cancers, low immunogenicity. We developing technologies efficiently transfer genes including suicide that will be used suppress tumor growth or ensure safety against possible adverse events develop off-the-shelf formulations allogeneic uses. MSCs were engineered express a gene encoding non-human cytosine deaminase (CD) enzymes. aimed...
Among gliomas, the most common primary malignant brain tumor, incidental gliomas account for 2.5%-5% of cases. The controversy over whether to pursue immediate treatment or adopt a wait-and-see approach remains, and more molecular immunological evidence is needed definitive decisions.
Abstract PURPOSE LLT-1 is a well-known ligand for the natural killer (NK) cell inhibitory receptor NKRP1A. Here, we examined NLRC4 inflammasome components and expression in glioblastoma (GBM) tissues to elucidate potential associations interactions between these factors. METHODS Nine GBM were collected experiments RNA sequencing, while fifty-two tumor core sequencing. Expression of other proteins was assessed by immunofluorescence. Computational analyses utilized RNA-seq data from 296 52...
Abstract The inherent characteristics of glioblastoma multiforme (GBM), including tumoral heterogeneity and invasive capacity, combined with the presence blood-brain tumor barrier (BBTB), present challenges in developing effective treatment for GBM. Especially, margins GBM, where GBM cells infiltrate normal brain tissue, exhibit high resistance to therapies. Despite difficulties controlling progression from this region, margin remains a critical area be studied. Here we report...
Several limitations are associated with the early diagnosis and treatment of incidental lower-grade glioma (iLGG), due to its unknown molecular features, management is categorized as either "wait-and-see" strategy or immediate treatment. Therefore, in this study authors explored iLGG's clinical landscape improve management.The retrospectively assessed differences between characteristics iLGG symptomatic (sLGG) samples filtered based on symptom data corresponding The Cancer Genome Atlas...
Inflammasomes are key in the initiation of inflammatory responses and serve to defend organism. However, when immune system is imbalanced, these complexes contribute tumor progression. The purpose this study was investigate effect non-canonical inflammasomes on glioma malignancy.We performed bioinformatics analysis confirm expression canonical inflammasome-related molecules according degree malignancy through immunohistochemical examination tissues obtained with patient consent from our...
Abstract Glioblastoma (GBM) is the most lethal brain tumors with intensive resistance to drug. Although glioblastoma has been tried treat diverse strategies, drug still concerning. Finding new therapeutic targets improve conventional sensitivity remained a major challenge. Here, novel target, FOSL1, resistant patients was established, in which FOSL1 knockdown restores temozolomide (TMZ) via regulation of IL-6-induced stemness characteristic cells. We show that contributing poor prognosis GBM...